Investor & Media


AiViva is dedicated to teaming with strategic partners and investors who share our vision and commitment to bring transformative therapies within our areas of focus in Ophthalmology, Dermatology, Urology, and Oncology. We also welcome the opportunity to explore novel applications of our JEL™ Technology in therapeutic areas of interest.

Please inquire by providing your contact information below:

Company Profile

AiViva is focused on developing targeted therapy for unmet needs in Ophthalmology, Dermatology, Urology, and Oncology.  Our targeted approach is derived from our patented JEL™ technology, which allows treatment to be delivered directly to the source.

Press Releases:

      October 2, 2020
      AiViva BioPharma Initiates Phase 1 / 2 Clinical Trial of AIV001 for Nonmelanoma Skin Cancer

      June 25, 2020
      AiViva BioPharma Announces Positive Date from Phase 1 / 2a Clinical Trial of AIV001 for
      Dermal Scarring and Wound Healing 


      AiViva BioPharma is Recognized by Life Sciences Review


      Upcoming Events
Coming Soon...
      Past Events